Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico / Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: Report of one case
Rev. méd. Chile
; 133(6): 681-684, jun. 2005.
Article
en Es
| LILACS
| ID: lil-429123
Biblioteca responsable:
BR1.1
ABSTRACT
New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m2 for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later.
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Factores Inmunológicos
/
Lupus Eritematoso Sistémico
/
Anticuerpos Monoclonales
Límite:
Adolescent
/
Female
/
Humans
Idioma:
Es
Revista:
Rev. méd. Chile
Asunto de la revista:
MEDICINA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Chile
Pais de publicación:
Chile